HCB101

汉康生技携“临床锚定到平台拓展” 战略亮相 BIO Asia–Taiwan 2026 口头报告与L221展位将聚焦HCB101临床开发、FBDB™平台拓展及全球合作机会 【台北、上海、旧金山｜2026年7月14日】——汉康生技股份有限公司（HanchorBio, Inc.，股票代码：7827，以下简称“汉康生技”），一家专注于肿瘤及免疫相关疾病新一代免疫疗法研发的全球临床阶段生物技术公司，今日宣布将参加2026亚洲生技大会（BIO Asia–Taiwan 2026）。大会将于2026年7月16日至19日在台北举行。 此次参会，正值汉康生技在临床开发、监管策略、科学合作、全球商务拓展及资本市场沟通等方面持续取得重要进展。这些进展并非彼此独立，而是共同体现了一条清晰的发展路径：以HCB101建立临床锚点，从临床和转化研究中学习生物学规律，再基于机制驱动合理拓展联合治疗与平台化开发机会。 免疫，从来不止一面。我们，也一样。 这也是汉康生技始终坚持的新药研发理念：从临床证据出发，遵循生物学规律，打造下一代多功能免疫疗法。 临床开发、监管策略与合作布局持续推进 HCB101是汉康生技自主研发的工程化SIRPα-IgG4 Fc融合蛋白，也是公司目前最重要的临床锚定资产。HCB101以CD47–SIRPα通路为核心，定位为具有潜力的髓系免疫增强治疗骨干（myeloid-enhancing immune backbone），并支持后续合理联合治疗策略的开发。 近期，公司在日本京都举行的JCA–AACR特别联合会议上公布了HCB101在胃癌/胃食管结合部癌及头颈部鳞状细胞癌中的临床数据，为后续开发策略提供了更多临床和转化研究依据。目前，二线胃癌/胃食管结合部癌仍是HCB101的核心开发方向；与此同时，公司也正基于持续积累的临床观察，评估其在髓系生物学、免疫排斥及治疗耐药更为显著的肿瘤类型中的拓展机会。 公司近期与美国FDA完成Type C沟通，进一步明确了HCB101在二线胃癌/胃食管结合部癌中的下一阶段开发路径。未来，公司将继续推进HCB101联合ramucirumab及paclitaxel的剂量和给药方案优化，并计划通过随机化Phase 2b lead-in设计衔接后续确认性临床开发。 与此同时，公司正持续推进基于生物学驱动的联合治疗策略，进一步拓展HCB101的开发潜力。近期，公司宣布与应世生物（InxMed）签署战略合作备忘录，共同探索互补机制，以突破难治性实体瘤中的肿瘤微环境屏障。 在BIO Asia–Taiwan集中展示公司战略 BIO Asia–Taiwan期间，汉康生技将通过科学报告和展位交流，系统展示公司“临床锚定到平台拓展”的发展战略。 2026年7月17日，公司首席科学官翟文武博士将发表口头报告，题为：Redefining Immuno-Oncology Through Multi-Functional Fc-Based Designer Biologics (FBDB) Platform 报告将介绍汉康生技如何依托FBDB™平台设计多功能生物药，将互补免疫机制整合至单一分子架构，并进一步阐述临床资产与平台拓展战略之间的内在联系。 大会期间，公司还将在L221展位展示HCB101临床开发策略、整体研发管线、新一代FBDB™平台项目，以及产品授权、联合治疗开发和共同开发等合作机会。 从美国到亚洲，延续全球对话 汉康生技此次带到BIO Asia–Taiwan的讨论，并非始于台北。 近几周，公司持续与全球生物医药生态系统中的合作伙伴展开交流，围绕一个核心问题展开讨论： 如何将临床验证的髓系免疫策略，进一步拓展为更广泛的免疫治疗平台？ 在BIO International 2026期间，公司商务拓展团队通过BIO Partnering™与全球生物技术、制药企业及战略合作伙伴进行了深入交流。同时，公司管理团队还在纽约和波士顿与机构投资者及资本市场人士会面，介绍汉康生技“临床锚定到平台拓展”战略及全球发展规划。 这些交流进一步凸显了汉康生技与第一代CD47项目的差异化发展思路。公司并非简单重复已有CD47开发路径，而是以差异化SIRPα临床资产为基础，通过严谨的临床和监管执行，并依据不断积累的证据推进合理联合治疗及下一代多轴免疫疗法开发。 BIO Asia–Taiwan将进一步汇聚这些关键进展：新的临床证据、更清晰的监管路径、生物学驱动的合作、全球商务拓展，以及美国资本市场交流，共同展现汉康生技如何整合临床、科研、合作与资本市场资源，持续推进全球化发展。 从临床锚定到平台拓展 汉康生技的发展战略始于HCB101，但并不止于HCB101。 HCB101积累的临床和转化研究经验，正持续推动公司更广泛的FBDB™平台战略。包括HCB301和HCB303在内的后续项目，将平台进一步拓展至多轴免疫疗法；其他项目则探索髓系生物学在肿瘤之外疾病领域中的潜在应用。 临床锚定 → 合理拓展 → 平台选择。 汉康生技创始人、董事长刘世高博士表示：“BIO Asia–Taiwan对于汉康生技来说正逢其时。近期在临床开发、监管规划、联合治疗策略及全球合作方面取得的进展，让我们更加清晰地看到下一阶段的发展方向。HCB101是我们的临床锚点，FBDB™是我们的平台引擎，而合作则是拓展平台价值的重要方式。” 刘博士进一步表示：“汉康生技正在连接亚洲创新、全球临床开发与国际合作资源。BIO Asia–Taiwan为我们提供了一个重要平台，将持续积累的临床证据、不断深化的生物学认知，以及能够加速发展的合作伙伴连接在一起。免疫，从来不止一面。我们，也一样。我们相信，下一代免疫疗法也应建立在这一现实基础之上。” 关于汉康-KY 英属开曼群岛商汉康生技股份有限公司（以下简称“汉康-KY”，股票代码：7827）是一家全球临床阶段生物技术公司，致力于开发面向肿瘤及免疫相关疾病的新一代免疫疗法。 公司自主建立的 Fc-Based Designer Biologics（FBDB™）多功能生物药平台，可将互补性免疫机制整合于单一分子架构中，用于开发具有差异化作用机制的创新生物药。 汉康生技的临床管线以 HCB101 为核心锚点。HCB101 是一款工程化 SIRPα-IgG4 Fc 融合蛋白，旨在恢复巨噬细胞介导的抗肿瘤活性，并支持基于生物学机制的联合治疗策略开发。HCB301、HCB303 及其他后续项目则进一步将公司平台拓展至多轴免疫治疗及肿瘤以外的潜在疾病领域。 汉康生技在亚洲及美国设有运营团队，并持续推进临床开发、监管策略、全球合作及产品授权。公司坚持从临床证据出发，遵循生物学规律，推动创新药物从临床锚定走向平台化拓展。 更多公司信息请访问公司官网。 前瞻性声明 本新闻稿及同时发布之相关信息内含预测性叙述；其内容乃根据既有之风险及可能的不确定性进行判断及预测，包括：市场因素与其他非汉康-KY（以下简称本公司）所能掌控之原因。这些预测性叙述是基于现况的预测和评估，除非基于法律的要求，本公司不负日后更新之责。 HanchorBio Brings Clinical Anchor-to-Platform Strategy to BIO Asia–Taiwan 2026 Oral presentation and Booth L221 to connect HCB101 clinical development, FBDB™ platform expansion, and global collaboration opportunities [Taipei, Shanghai, San Francisco | July 14, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-related diseases, today announced that it will present its clinical development and platform strategy at BIO Asia–Taiwan 2026, taking place July 16–19, 2026, in Taipei, Taiwan. HanchorBio comes to BIO Asia–Taiwan following a period of progress across clinical development, regulatory strategy, scientific collaboration, global partnering, and capital-market engagement. Together, these activities reflect a clear development model: establish a strong clinical anchor, learn from the biology emerging around it, expand through rational combinations, and translate those learnings into the next generation of multi-functional immunotherapies. Immunity was never one-dimensional. Neither are we. That belief shapes how HanchorBio develops medicines: start with evidence, follow the biology, and build what comes next. Recent Momentum Across Clinical Development, Regulatory Strategy, and Collaboration HCB101, HanchorBio’s engineered SIRPα-IgG4 Fc fusion protein, serves as the Company’s lead clinical anchor and is being developed as a potential myeloid-enhancing immune backbone for rational combination therapy.  Recent clinical data presented at the JCA–AACR Special Joint Conference in Kyoto provided additional evidence in gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma. Second-line gastric/GEJ cancer remains the lead development setting for HCB101, while emerging clinical and translational learnings are guiding the evaluation of selected expansion opportunities in tumor settings where myeloid biology, immune exclusion, and treatment resistance may play important roles. The Company’s recent FDA Type C interaction further clarified the next stage of HCB101 development in second-line gastric/GEJ cancer, supporting continued dose and schedule optimization in combination with ramucirumab and paclitaxel, followed by a planned randomized Phase 2b lead-in strategy toward confirmatory development. In parallel, HanchorBio is extending its strategy through biology-driven combinations. The Company’s recently announced strategic MOU with InxMed to explore complementary approaches to overcoming tumor microenvironment barriers in difficult-to-treat solid tumors. Bringing the Strategy Together at BIO Asia–Taiwan At BIO Asia–Taiwan, HanchorBio will bring these elements together through both scientific presentation and direct engagement with potential partners, collaborators, and investors. On July 17, 2026, Wenwu Zhai, Ph.D., Chief Scientific Officer of HanchorBio, will deliver an oral presentation titled “Redefining Immuno-Oncology Through Multi-Functional Fc-Based Designer Biologics (FBDB) Platform.” The presentation will describe HanchorBio’s approach to designing multi-functional biologics that bring complementary immune mechanisms together within a single molecular architecture, as well as the relationship between the Company’s clinical programs and its broader FBDB™ platform strategy. Throughout the conference, HanchorBio will also exhibit at Booth L221, where the Company will showcase the HCB101 development strategy, its broader clinical pipeline, next-generation FBDB™ programs, and opportunities for licensing, combination development, and co-development. Extending Global Engagement from the United States to Asia The discussions HanchorBio brings to BIO Asia–Taiwan did not begin in Taipei. In recent weeks, the Company has been engaging different parts of the global biotechnology ecosystem around a central question: how can a clinically informed myeloid strategy become a broader immunotherapy platform? At BIO International 2026, HanchorBio’s business development team engaged with global biotechnology, pharmaceutical, and strategic partners. In parallel, Company leadership met with institutional investors and capital-market participants in New York and Boston to discuss HanchorBio’s clinical anchor-to-platform strategy and global development plans. These conversations have also reinforced the importance of distinguishing HanchorBio’s strategy from first-generation CD47 drug development. The Company is building from a differentiated SIRPα-based clinical anchor, applying disciplined clinical and regulatory development, and using emerging evidence to guide rational combinations and next-generation multi-axis biologics. BIO Asia–Taiwan now brings these threads together: new clinical evidence, a clearer regulatory path, biology-driven collaboration, global partnering, and U.S. capital-market engagement—at home, for a company building globally. From Clinical Anchor to Platform Expansion HanchorBio’s strategy begins with HCB101, but it does not end there. Clinical and translational learnings from HCB101 are informing the Company’s broader FBDB™ platform strategy. Programs including HCB301 and HCB303 extend the approach toward multi-axis immunotherapy, while additional programs explore the relevance of myeloid biology beyond oncology. Clinical anchor → rational expansion → platform optionality. “BIO Asia–Taiwan comes at the right moment for HanchorBio,” said Scott Liu, Ph.D., Founder and Chairman of HanchorBio. “Recent progress across clinical development, regulatory planning, combination strategy, and global engagement has brought greater clarity to how we build from here. HCB101 is our clinical anchor. FBDB™ is our platform engine. Collaboration is how we expand the opportunity.” “With our roots in Taiwan and building globally. BIO Asia–Taiwan gives us an important home-market platform to connect the clinical evidence we are generating, the biology we are learning from, and the partnerships that can help us move faster. Immunity was never one-dimensional. We believe the next generation of immunotherapy should be designed with that reality in mind.” About HanchorBio HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies based on a fundamental belief: immunity is not one-dimensional, and the medicines designed to harness it should not be either. Rooted in Taiwan with operations in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is advancing a pipeline of immunotherapies for oncology and immune-mediated diseases. The Company’s proprietary Fc-Based Designer Biologics (FBDB™) platform enables the design of multi-functional biologics that bring complementary immune mechanisms together within a single molecular architecture. HanchorBio’s clinical pipeline is anchored by HCB101, an engineered SIRPα-IgG4 Fc fusion protein designed to restore macrophage-mediated antitumor activity and enable rational combination strategies. Clinical and translational learnings from HCB101 inform the Company’s broader platform expansion, including multi-axis immunotherapies and programs beyond oncology. Listed on the Taiwan Stock Exchange Innovation Board (TWSE: 7827), HanchorBio is advancing its clinical development, regulatory strategy, and global partnerships from a foundation built in Taiwan and designed for global development. Forward-Looking Statements This press release contains forward-looking statements regarding HanchorBio’s clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions and decisions, protocol development, execution of collaboration, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.